Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 12/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL5076823 | 0.95 | KDM4E (0.48) | KDM4EALDH1A1HSD17B10MTNR1AMTNR1B | |
| SCHEMBL2475349 | 0.77 | ALDH1A1 (0.61) | ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL8065405 | 0.77 | MTNR1A (0.67) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL7635281 | 0.76 | MTNR1A (0.51) | ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL8258560 | 0.76 | MTNR1A (0.52) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL27622596 | 0.76 | MTNR1A (0.51) | KDM4EALDH1A1HSD17B10MTNR1AMTNR1B | |
| SCHEMBL5071575 | 0.76 | RXFP1 (0.57) | KDM4EALDH1A1HSD17B10MTNR1AMTNR1B | |
| SCHEMBL5072892 | 0.75 | PKM (0.66) | KDM4EALDH1A1 | |
| SCHEMBL27678383 | 0.74 | P2RX7 (0.54) | — | |
| SCHEMBL3166962 | 0.73 | PKM (0.51) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-12-18 | — | — | US | disclosed |
| US-7427613-B2 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-23 | — | — | US | disclosed |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | KDM4E 799/4885ALDH1A1 391/4885HSD17B10 305/4885 |
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | REN, AGTR1, ACE | KDM4E 799/4885ALDH1A1 391/4885HSD17B10 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.